CME commercial support flat in '07

Total commercial support of CME scarcely budged in 2007, rising 1% to $1.2 billion, while the share of commercial support going to publishing and education companies declined 4.2% to $594 million, according to the ACCME's annual report. 

Medical publishers and med ed agencies weren't the only providers to see support slide, data from the Accreditation Council for Continuing Medical Education show. Commercial support to government and military providers fell a whopping 94%, while support to hospitals plunged 18% and that going to medical schools fell 5%. 

Those gaining in commercial support: specialist societies and other non-profits, as well as insurance and managed care companies. 

Total income reported was nonetheless up 6.5% overall, while the number of physician participants rose 5.4% and the number of CME activities increased by 20.8%.
 
However, the drop in commercial support suggests that congressional inquiries into industry funding of CME and criticism within academic and medical circles may be having an impact. 

Tom Sullivan, president of med ed firm Rockpointe Corp., said the reality is probably worse than the data suggests. 

“I'm wondering if people are over-reporting,” said Sullivan. “I think there's probably been a drop in support and it's showing up as static because people are being more diligent in how they report.” Some firms, he suggested, may be including advertising and exhibits income, which is not considered commercial support, just to be on the safe side at a time of intense scrutiny on CME funding. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.